Table 1.
Association between SLE status and anti-EBV antibodies in age- and sex-matched cases and controls.
| Anti-EBV antibodies1 | SLE5 | Controls | Conditional logistic regression2 | Attributable fraction3 | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | p4 | |||||
| Anti-VCA IgG | POS | 232 | 642 | 28.59 (6.42–∞) | 8.83 × 10-8 | 100% |
| NEG | 0 | 54 | ||||
| Anti-EBNA1 IgG in Anti-VCA IgG POS | POS | 124 | 232 | 9.74 (1.49–414.34) | 0.0078 | 89.7% |
| NEG | 1 | 18 | ||||
| Anti-VCA IgA in Anti-VCA IgG POS | POS | 72 | 56 | 3.47 (2.27–5.29) | 5.7 × 10-8 | 71.2% |
| NEG | 85 | 258 | ||||
1Anti-Epstein–Barr virus (EBV) viral capsid antigen (VCA) IgG or IgA and anti-Epstein–Barr nuclear antigen 1 (EBNA1) IgG-positive (POS) or -negative (NEG) test result. Controls are matched to each case by age (6–75 years) and sex.
2The exact test is used for anti-VCA IgG and anti-EBNA1 in anti-VCA IgG POS.
3The fraction of systemic lupus erythematosus (SLE) cases attributable to the positive antibody result being tested in each instance, estimated from the odds ratio (OR).
4One-tailed p values and median unbiased estimates of OR from exact conditional logistic regression are presented for anti-VCA IgG and anti-EBNA1 IgG in anti-VCA IgG POS cases and controls.
5The cases and assigned matched controls used in these analyses are presented in Supplemental Table S1 . Original data are from Cui et al. (1).